Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targeting.
Francesca FontanaAlison K EsserChristopher EgbulefuPartha KarmakarXinming SuJohn S AllenYalin XuJennifer L DavisAriel GabayJingyu XiangKristin A KwakwaBrad ManionSuzanne BakewellShunqiang LiHaeseong ParkGregory M LanzaSamuel AchilefuKatherine N WeilbaecherPublished in: PloS one (2023)
TfR is expressed in breast cancer, primary, metastatic, and after neoadjuvant chemotherapy. Variability in expression of TfR suggests that evaluation of the expression of TfR in individual patients could identify the best candidates for targeting. Further, systemic iron chelation with DFO may upregulate receptor expression and improve uptake of therapeutics or tracers that use transferrin as a homing ligand.
Keyphrases
- neoadjuvant chemotherapy
- poor prognosis
- metastatic breast cancer
- end stage renal disease
- binding protein
- squamous cell carcinoma
- newly diagnosed
- cancer therapy
- chronic kidney disease
- locally advanced
- ejection fraction
- small cell lung cancer
- lymph node
- long non coding rna
- prognostic factors
- small molecule
- sentinel lymph node
- radiation therapy
- early stage
- drug delivery
- single molecule